Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuo Yoshioka

Showing results (1-10 of 386) with videos related to

Pageof 39
Sort By:
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|February 8, 2011
[Nanosafety studies of nanomaterials about biodistribution and immunotoxicity]Yasuo Yoshioka
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|August 7, 2004
[Creation of functional muteins using phage libraries for pharmacoproteomic-based drug discovery and development of DDS]Yasuo Yoshioka
International Journal of Clinical Oncology|February 20, 2009
Current status and perspectives of brachytherapy for prostate cancerYasuo Yoshioka
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 28, 2016
[High-dose-rate brachytherapy]Yasuo Yoshioka
International Journal of Urology : Official Journal of the Japanese Urological Association|February 19, 2015
Editorial Comment to Therapeutic outcomes of neoadjuvant and concurrent androgen-deprivation therapy and intensity-modulated radiation therapy with gold marker implantation for intermediate and high-risk prostate cancerYasuo Yoshioka
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|September 1, 2007
Prostate Risk Index (PRIX) as a new method of risk classification for clinically localized prostate cancerYasuo Yoshioka, Takehiro Inoue
Nature Nanotechnology|December 8, 2011
Quantifying the biodistribution of nanoparticlesYasuo Tsutsumi, Yasuo Yoshioka
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|June 3, 2014
[Nano-safety science for sustainable nanotechnology]Yasuo Yoshioka, Yasuo Tsutsumi
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|March 3, 2012
[Safety assessment of nanomaterials in reproductive developmental field]Kohei Yamashita, Yasuo Yoshioka
Frontiers in Immunology|July 1, 2022
Considerations of CD8<sup>+</sup> T Cells for Optimized Vaccine Strategies Against Respiratory VirusesToshiro Hirai, Yasuo Yoshioka
Pageof 39

Showing results (1-10 of 386) with videos related to

Sort By:
Pageof 39
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|February 8, 2011
[Nanosafety studies of nanomaterials about biodistribution and immunotoxicity]Yasuo Yoshioka
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|August 7, 2004
[Creation of functional muteins using phage libraries for pharmacoproteomic-based drug discovery and development of DDS]Yasuo Yoshioka
International Journal of Clinical Oncology|February 20, 2009
Current status and perspectives of brachytherapy for prostate cancerYasuo Yoshioka
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 28, 2016
[High-dose-rate brachytherapy]Yasuo Yoshioka
International Journal of Urology : Official Journal of the Japanese Urological Association|February 19, 2015
Editorial Comment to Therapeutic outcomes of neoadjuvant and concurrent androgen-deprivation therapy and intensity-modulated radiation therapy with gold marker implantation for intermediate and high-risk prostate cancerYasuo Yoshioka
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|September 1, 2007
Prostate Risk Index (PRIX) as a new method of risk classification for clinically localized prostate cancerYasuo Yoshioka, Takehiro Inoue
Nature Nanotechnology|December 8, 2011
Quantifying the biodistribution of nanoparticlesYasuo Tsutsumi, Yasuo Yoshioka
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|June 3, 2014
[Nano-safety science for sustainable nanotechnology]Yasuo Yoshioka, Yasuo Tsutsumi
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|March 3, 2012
[Safety assessment of nanomaterials in reproductive developmental field]Kohei Yamashita, Yasuo Yoshioka
Frontiers in Immunology|July 1, 2022
Considerations of CD8<sup>+</sup> T Cells for Optimized Vaccine Strategies Against Respiratory VirusesToshiro Hirai, Yasuo Yoshioka
Pageof 39